Works by KRENNING, E. P.


Results: 33
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    FDG SPECT in the assessment of myocardial viability.

    Published in:
    European Heart Journal, 1997, v. 18, n. suppl_D, p. 124, doi. 10.1093/eurheartj/18.suppl_D.124
    By:
    • Bax, J.J.;
    • Valkema, R.;
    • Visser, F. C.;
    • van Lingen, A.;
    • Cornel, J. H.;
    • Poldermans, D.;
    • Rambaldi, R.;
    • Krenning, E. P.;
    • Fioretti, P. M.
    Publication type:
    Article
    13
    14

    Somatostatin and the immune and haematopoetic system; a review.

    Published in:
    European Journal of Clinical Investigation, 1994, v. 24, n. 2, p. 91, doi. 10.1111/j.1365-2362.1994.tb00972.x
    By:
    • HAGEN, P. M. VAN;
    • KRENNING, E. P.;
    • KWEKKEBOOM, D. J.;
    • REUBI, J. C.;
    • ANKER-LUGTENBURG, Vd. P. J.;
    • LÖWENBERG, B.;
    • LAMBERTS, S. W. J.
    Publication type:
    Article
    15
    16
    17

    Somatostatin analogue scintigraphy of malignant lymphomas.

    Published in:
    British Journal of Haematology, 1993, v. 83, n. 1, p. 75, doi. 10.1111/j.1365-2141.1993.tb04634.x
    By:
    • Vanhagen, P. M.;
    • Krenning, E. P.;
    • Reubi, J. C.;
    • Mulder, A. H.;
    • Bakker, W. H.;
    • Oei, H. Y.;
    • Löwenberg, B.;
    • Lamberts, S. W. J.
    Publication type:
    Article
    18

    Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2011, v. 38, n. 7, p. 1257, doi. 10.1007/s00259-011-1775-3
    By:
    • Schroeder, Rogier P. J.;
    • Weerden, W. M.;
    • Krenning, E. P.;
    • Bangma, C. H.;
    • Berndsen, S.;
    • Grievink-de Ligt, C. H.;
    • Groen, H. C.;
    • Reneman, S.;
    • Blois, E.;
    • Breeman, W. A. P.;
    • Jong, M. de
    Publication type:
    Article
    19
    20
    21
    22
    23

    Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [[sup 177] Lu-DOTA[sup 0] ,Tyr[sup 3] ]octreotate.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2003, v. 30, n. 3, p. 417, doi. 10.1007/s00259-002-1050-8
    By:
    • Kwekkeboom, D. J.;
    • Bakker, W. H.;
    • Kam, B. L.;
    • Teunissen, J. J. M.;
    • Kooij, P. P. M.;
    • de Herder, W. W.;
    • Feelders, R. A.;
    • van Eijck, C. H. J.;
    • de Jong, M.;
    • Srinivasan, A.;
    • Erion, J. L.;
    • Krenning, E. P.
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33